Hvsen Biotechnology Co., Ltd.

300871

CNE1000047H6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
15.48 ^CNY	+0.19%		+0.19%	+7.05%

Apr. 25	Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023	CI
Apr. 24	Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.

October 09, 2022 at 12:00 pm EDT

From July 1, 2022 to September 30, 2022, the company has repurchased 1,266,150 shares, representing 0.76% for CNY 26.09 million. With this, the company has completed the repurchase of 1,522,850 shares, representing 0.92% for CNY 30.95 million under the buyback announced on April 22, 2022.

Latest news about Hvsen Biotechnology Co., Ltd.

Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023	Apr. 24	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Hvsen Biotechnology Co., Ltd. announced a financing transaction	Apr. 02	CI
Tech-Bank Food Co., Ltd. announced that it has received CNY 1.197979975 billion in funding from a group of investors	Dec. 28	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Certain A Shares of Hvsen Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Hvsen Biotechnology Co., Ltd. Implements Cash Dividend of A Shares for 2022, Payable on 21 June 2023	23-06-15	CI
Hvsen Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2022	23-05-18	CI
Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-27	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.	23-04-25	CI
Hvsen Biotechnology Co., Ltd.'s Equity Buyback announced on April 22, 2022, has expired with 2,389,050 shares, representing 1.44% for CNY 50.02 million.	23-04-20	CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.	23-04-03	CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.	23-01-03	CI
Hvsen Biotechnology Co., Ltd. Approves Board Appointments	22-12-12	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Hubei Huisheng Biotechnology Co., Ltd. announced that it expects to receive CNY 700 million in funding from Hvsen Biotechnology Co., Ltd.	22-10-24	CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.	22-10-09	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Certain A Shares of Hvsen Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-AUG-2022.	22-08-23	CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.	22-07-01	CI
Hvsen Biotechnology Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	22-04-22	CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-22	CI

Chart Hvsen Biotechnology Co., Ltd.

Duration

Period

More charts

Company Profile

Wuhan Hvsen Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of veterinary drugs, feed and additives. The Companyâs main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The Company mainly conducts its businesses in the China market.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hvsen Biotechnology Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.48

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
HVSEN BIOTECHNOLOGY CO., LTD.	+7.05%	350M
ZOETIS INC.	-11.83%	79.42B
BLUESTAR ADISSEO COMPANY	+28.00%	3.8B
VIRBAC	-1.39%	3.23B
VIMIAN GROUP AB	+21.28%	1.75B
JINYU BIO-TECHNOLOGY CO., LTD.	-3.25%	1.61B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-18.63%	1.36B
VETOQUINOL SA	-1.17%	1.3B
WUHAN KEQIAN BIOLOGY CO.,LTD	-6.77%	1.22B
PULIKE BIOLOGICAL ENGINEERING, INC.	+2.34%	1.11B

Veterinary Drugs

Hvsen Biotechnology Co., Ltd.

Equities

300871

CNE1000047H6

Pharmaceuticals

Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.

Latest news about Hvsen Biotechnology Co., Ltd.

Chart Hvsen Biotechnology Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Hvsen Biotechnology Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Veterinary Drugs